AstraZeneca and Daiichi Sankyo entered a global collaboration to jointly develop and commercialize datopotamab deruxtecan (DS-1062), a TROP2-directed antibody-drug conjugate. AstraZeneca paid $1 billion upfront in staged payments ($350M at execution, $325M at 12 months, $325M at 24 months) with up to $5 billion in regulatory and sales milestones. This was the second major AZ-Daiichi ADC collaboration following the 2019 Enhertu deal. Daiichi Sankyo retained exclusive rights in Japan.
Key facts
AnnouncedJul 27, 2020
ClosedJul 27, 2020
Deal value$6.0B
Deal typeLicensing/Option
Therapeutic areaOncology
IndicationsNon-Small Cell Lung Cancer, Breast Cancer, Solid Tumors